Skip to main content

Bladder Cancer

Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin

Sacituzumab plus Pembrolizumab Shows Promising Antitumor Activity in Metastatic Urothelial Cancer

Recent Targeted Therapies Approved for the Treatment of Patients with Urothelial Carcinoma

Bojana Stevich-Heemer, MS, PharmD, MEd, BCOP

Enfortumab Vedotin Superior to Chemotherapy in Urothelial Cancer

FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Results 1 - 7 of 7